ALSO NOTED: Strativa acquires Onconase rights; Neurocrine gets new CEO; SAFC plans biologics expansion; and much more...

> Strativa has acquired commercialization rights to the late-stage Onconase from Alfacell. Onconase is in Phase III for inoperable malignant mesothelioma, a rare form of cancer. Alfacell gets $5 million up front and another $30 million on FDA approval. Report

> Chutes & Ladders: Gary Lyons is stepping down as CEO of Neurocrine Biosciences, making way for COO Kevin Gorman, Ph.D. Lyons will stay on the board. Release

> SAFC is planning a $12 million expansion of its biologics manufacturing facility. Release

> VGX Pharmaceuticals announced that the FDA accepted the Investigational New Drug application for its lead anti-inflammatory compound, VGX-1027. Release

> Molecular Partners inked a collaborative research and license deal with Centocor Research & Development. The collaboration will focus on the development of DARPins--Designed Ankyrin Repeat Proteins--a novel class of therapeutic proteins to treat inflammatory diseases. Release

> Call it the comeback kid. Tysabri nabbed a new indication from the FDA yesterday, as a second-line treatment for the intestinal disorder Crohn's disease. Report

> If GlaxoSmithKline can challenge Merck to a head-to-head trial (Cervarix versus Gardasil), then AstraZeneca can throw down the gauntlet before Pfizer. In this case, the products in question are statins--AstraZeneca's Crestor and Pfizer's Lipitor. Report

> Gardasil captured more territory for Merck and Sanofi-Aventis yesterday when French health officials recommended that vaccine against Human Papilloma Virus, or HPV. Report

> It's a pile-on. Experts and non-experts alike are expounding on yesterday's dismal ENHANCE results. For every cardiologist of unshaken faith, there are a half-dozen or more detractors gleefully trashing Merck and Schering-Plough. Report

And Finally… A landmark case aimed at requiring drug developers to make experimental therapies available to dying patients ended in a dead end yesterday as the Supreme Court declined to hear the case. Article

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.